(R)-CR8
Cat. No.：YN270365
| 产品名称: | (R)-CR8 |
| CAS No.: | 294646-77-8 |
| Chemical Name: | 2R-[[9-(1-methylethyl)-6-[[[4-(2-pyridinyl)phenyl]methyl]amino]-9H-purin-2-yl]amino]-1-butanol |
| Synonyms: | CR8, (R)-Isomer |
| 分子量: | 431.53 |
| 分子式: | C₂₄H₂₉N₇O |
| SMILES: | CC[C@@H](NC1=NC(NCC2=CC=C(C3=NC=CC=C3)C=C2)=C4N=CN(C(C)C)C4=N1)CO |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | (R)-CR8 (CR8) 是 Roscovitine 的第二代类似物，是一种有效的CDK1/2/5/7/9抑制剂。(R)-CR8 (CR8) 抑制 CDK1/cyclin B (IC50=0.09 μM)、CDK2/cyclin A (0.072 μM)、CDK2/cyclin E (0.041 μM)、CDK5/p25 (0.11 μM)、CDK7/cyclin H (1.1 μM)、CDK9/cyclin T (0.18 μM) 和 CK1δ/ε (0.4 μM)。(R)-CR8 (CR |
| IC50和靶点: | [{name:"Cdk1/cyclin B:0.09 μM (IC50)"},{name: "cdk2/cyclin A:0.072 μM (IC50)"},{name: "CDK2/cyclinE:0.041 μM (IC50)"},{name: "Cdk5/p25:0.11 μM (IC50)"},{name: "CDK7/cyclin H:1.1 μM (IC50)"},{name: "CDK9/Cyclin T:0.18 μM (IC50)"},{name: "CK1δ/ε:0.4 μM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Bettayeb, K., Baunbaek, D., Delehouze, C., et al.CDK inhibitors roscovitine and CR8 trigger Mcl-I down-regulation and apoptotic cell death in neuroblastoma cellsGenes Cancer1(4),369-380(2010)
Bettayeb, K., Oumata, N., Echalier, A., et al.CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinasesOncogene27(44),5797-5807(2008)
Oumata, N., Bettayeb, K., Ferandin, Y., et al.Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1J. Med. Chem.51(17),5229-5242(2008)
